OKUR · OnKure Therapeutics, Inc. · Executive Compensation
$2.60
+0.12 (+4.85%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the 2026 Private Placement (see Note 9), management believes the Company's cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these condensed consolidated financial statements and as such substantial doubt has been alleviated.”View the 10-Q filed Aug 4, 2026
Market Cap
$105.09M
Shares
40.50M
Volume · Oct 27
320.24K
Avg daily vol (3M)
255.87K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Nicholas A. Saccomano | President and Chief Executive Officer | $1,467,934 |
| Jason Leverone | C.P.A. Chief Financial Officer | $896,167 |
| Samuel Agresta | Chief Medical Officer | $851,731 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Nicholas A. Saccomano | President and Chief Executive Officer | $9,515,165 |
| Samuel Agresta | Chief Medical Officer | $2,841,068 |
| Jason Leverone | C.P.A. Chief Financial Officer | $2,678,570 |
| Gregory J. Flesher | Former President and Chief Executive Officer | $1,779,607 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jason Leverone | C.P.A. Chief Financial Officer | $791,947 |
| Gregory J. Flesher | Former President and Chief Executive Officer | $569,704 |
| Nicholas A. Saccomano | President and Chief Executive Officer | $308,852 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Gregory J. Flesher | President and Chief Executive Officer | $1,193,452 |
| Ashley F. Hall | Chief Development Officer | $825,304 |
| Michael P. Cruse | Chief Operating Officer | $781,474 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Gregory J. Flesher | President and Chief Executive Officer | $5,369,470 |
| Michael P. Cruse | Chief Operating Officer | $1,496,036 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Gregory J. Flesher | Chief Executive Officer and President | $132,947 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Edward T. Mathers | Class II director | Appointed | 2026-06-04 |
| Valerie M. Jansen | Class II director | Appointed | 2026-06-04 |
| R. Michael Carruthers | Class II director | Appointed | 2026-06-04 |
| Dr. Liam Ratcliffe | Class I director | Appointed | 2026-03-30 |
| Valerie M. Jansen | member of the Board of Directors of OnKure | Appointed | 2024-10-08 |
| Nicholas A. Saccomano | President and Chief Executive Officer of OnKure | Appointed | 2024-10-08 |
| Andrew Phillips | Chair of the Board | Appointed | 2024-10-08 |
| Edward T. Mathers | Class II director | Appointed | 2024-10-08 |
| Andrew Phillips | Class III director | Appointed | 2024-10-08 |
| Michael Grey | Class III director | Appointed | 2024-10-08 |
| Valerie M. Jansen | Class II director | Appointed | 2024-10-08 |
| R. Michael Carruthers | Class II director | Appointed | 2024-10-08 |
| Isaac Manke | Class I director | Appointed | 2024-10-08 |
| Nicholas Saccomano | Class I director | Appointed | 2024-10-08 |
| Dylan Hartley | Chief Scientific Officer | Appointed | 2024-10-08 |
| Samuel Agresta | Chief Medical Officer | Appointed | 2024-10-08 |
| Jason Leverone | Chief Financial Officer (Principal Financial and Accounting Officer) | Appointed | 2024-10-08 |
| Nicholas Saccomano | President and Chief Executive Officer (Principal Executive Officer) | Appointed | 2024-10-08 |
| Ashley F. Hall, J.D. | Chief Development Officer | Terminated | 2024-09-13 |
| Nicholas A. Saccomano, Ph.D. | President and Chief Executive Officer | Appointed | 2024-05-13 |
| Alejandro Dorenbaum | executive officer | Resigned | 2024-05-13 |
| Ashley F. Hall | executive officer | Resigned | 2024-05-13 |
| Jason Leverone | Chief Financial Officer | Appointed | 2024-05-13 |
| Nicholas A. Saccomano | President and Chief Executive Officer | Appointed | 2024-05-13 |
| Gregory J. Flesher | executive officer | Resigned | 2024-05-13 |
Leadership
- Nicholas A. Saccomano CEO, Board Member
- Nicholas A. Saccomano, Ph.D. CEO
- Nicholas Saccomano CEO, Board Member
- Andrew Phillips Chairman, Board Member
- Jason Leverone CFO
- Jennifer P. Lam CFO
- Michael P. Cruse COO
- Andrew Philips, Ph.D. Board Member
- Continuing Directors Board Member
- Dr. Liam Ratcliffe Board Member
- Edward T. Mathers Board Member
- Isaac Manke Board Member
- Isaac Manke, Ph.D. Board Member
- Liam Ratcliffe Board Member
- Michael Grey Board Member
- Paul Hoelscher Board Member
- R. Michael Carruthers Board Member
- Roshawn Blunt Board Member
- Valerie M. Jansen Board Member
- Valerie M. Jansen, M.D., Ph.D. Board Member